News & Updates

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

A recent study has found that laughing can be as effective as artificial tears (ie, 0.1% sodium hyaluronic acid eye drop) in relieving ocular surface discomfort in patients with dry eye disease (DED) with limited corneal staining.